Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
ANI Has Four-Pillar Growth Strategy Following Novitium Deal
As Company Sees Q4 Revenue Increase On The Back Of Generics Sales
Mar 22 2021
•
By
Akriti Seth
ANI Pharma announces a four-pillar growth strategy along with Q4 2020 results • Source: Shutterstock
More from Deals
More from Business
